Статті в журналах: "Covid long"

1

Kuznecova, Sof'ya, and Elena Belyaeva. "LONG COVID SYNDROME." Clinical Medicine and Pharmacology 9, no. 1 (May 15, 2023): 31–32. http://dx.doi.org/10.12737/2409-3750-2023-9-1-31-32.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Clinical observations of polymorbid patients with Long Covid syndrome in real clinical practice are presented. Treatment options for patients with lung, muscle, cardiovascular and nervous system damage, immuno-inflammatory syndrome are proposed.

2

Mihajlović, Miroslav, Bogdan Marković, Milan Marinković, Nebojša Mujović, and Tatjana Potpara. "Long COVID-19 syndrome: An overview." Medicinski podmladak 74, no. 4 (2023): 26–34. http://dx.doi.org/10.5937/mp74-47797.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The Long COVID-19 syndrome has emerged as global epidemic, affecting individuals after an acute infection caused by the Severe acute respiratory syndrome coronavirus 2, impacting multiple organs, including the heart. The most common symptoms encompass fatigue and shortness of breath, which could persist for months after an acute COVID-19 infection. Numerous studies have researched the pathophysiology of Long COVID-19 syndrome, suggesting that local tissue damage and hyperinflation could be employed as possible mechanisms of Long COVID-19 syndrome. Many blood biomarkers (blood urea nitrogen, D-dimer, lymphopenia, troponin-1, interleukin-6, and CRP) and clinical risk factors (CRP female sex, a history of psychiatric disorders, and the presence of more than five symptoms during the first week of an acute illness) are shown to be associated with the development of Long COVID-19 syndrome. Currently, the evidence-based specific pharmacological treatments for the Long COVID-19 syndrome are lacking. Several studies have shown an association between antiviral drugs (such as nirmatrelvir, ensitrelvir, and molnupiravir) and vaccination against COVID-19 with a reduced risk of developing Long COVID-19 syndrome. This narrative review discusses the possible pathophysiology, risk factors, and treatments for Long COVID-19 syndrome with particular reference to the cardiovascular system.

3

TICĂRĂU, Adriana, Mihaela Adela IANCU, and Dumitru MATEI. "Long COVID syndrome – general aspects." Romanian Journal of Medical Practice 16, no. 2 (June 30, 2021): 174–77. http://dx.doi.org/10.37897/rjmp.2021.2.12.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

2020), growing scientific evidence worldwide suggests that a small percentage of people who have developed COVID-19 and healed after the initial infection may experience a series of persistent symptoms over a period of more than 12 weeks, such as marked fatigue, shortness of breath, confusion, diarrhea, or other symptoms that cannot be explained by an alternative diagnosis. This status has been called “long COVID syndrome” or ”post COVID syndrome”.

4

Editor in Chief, The. "Long COVID." BIRDEM Medical Journal 11, no. 2 (April 23, 2021): 80–83. http://dx.doi.org/10.3329/birdem.v11i2.53126.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Visan, Ioana. "Long COVID." Nature Immunology 22, no. 8 (July 27, 2021): 934–35. http://dx.doi.org/10.1038/s41590-021-00992-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Hofman, Eline. "LONG COVID." TvPO 17, no. 1 (January 31, 2022): 20–22. http://dx.doi.org/10.1007/s12503-022-0927-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

S. N., Puzin, Potapov V. N., Bogova O. T., and Velikolug K. A. "MEDICAL REHABILITATION FOR LONG-COVID INFECTION." Bulletin of the Russian association of specialists in medical and social expert evaluation, rehabilitation and rehabilitation industry 4 (2023): 69–86. http://dx.doi.org/10.17238/issn1999-2351.2023.4.69-86.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Belotserkovskaya, Yulia G., Anna G. Romanovskikh, Igor P. Smirnov, and Alexander I. Sinopalnikov. "Long COVID-19." Consilium Medicum 23, no. 3 (2021): 261–68. http://dx.doi.org/10.26442/20751753.2021.3.200805.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The term “long COVID-19” describes the long-term effects of the novel coronavirus infection COVID-19. Patients with severe COVID-19 who require hospitalization, as well as those who are on outpatient treatment with mild clinical forms of the disease, often report persistent fatigue, shortness of breath, pain, cough and other respiratory and extrapulmonary symptoms for weeks and months. The generally accepted time frame that separates the duration of the acute and subacute phase of infection from the long COVID-19 is 28 days. The article describes the duration and the course of clinical disorders caused by COVID-19 and their persisting after the end of the acute phase of the disease. In addition, the current understanding of the causes of long-term consequences and the possibilities of drug and non-pharmacological correction are presented.

9

Di Toro, Alessandro, Antonio Bozzani, Guido Tavazzi, Mario Urtis, Lorenzo Giuliani, Roberto Pizzoccheri, Flaminia Aliberti, Viola Fergnani, and Eloisa Arbustini. "Long COVID: long-term effects?" European Heart Journal Supplements 23, Supplement_E (October 1, 2021): E1—E5. http://dx.doi.org/10.1093/eurheartj/suab080.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Abstract The term Long COVID (or Post COVID) describes a condition characterized by persistence of symptoms for at least 12 weeks after the onset of COVID-19. It may last several months but the duration is still matter of observation. The symptoms and the clinical manifestations are clinically heterogeneous and suggesting involvement of multi-organs/systems, including the cardiovascular system. The general recurrent symptoms include fatigue, breathlessness, myalgia, headache, loss of memory, and impaired concentration. Patients report loss of their previous psychophysical performance. Cardiovascular involvement manifests with common symptoms such as palpitations and chest pain, and, less commonly, with events such as late arterial and venous thromboembolisms, heart failure episodes, strokes or transient ischaemic attack, ‘myo-pericarditis’. The diagnostic criteria are mainly based on the narrative of the patients. Measurable biomarkers or instrumental findings or clinical events are not yet framed in a shared diagnostic framework. The open question for clinicians and researchers is whether biomarkers, electrocardiogram, non-invasive imaging, and clinical monitoring should be included in a shared diagnostic protocol aimed at defining the diagnostic path and protecting patients at risk of unexpected events.

10

Martelletti, Paolo, E. Bentivegna, V. Spuntarelli, and M. Luciani. "Long-COVID Headache." SN Comprehensive Clinical Medicine 3, no. 8 (May 20, 2021): 1704–6. http://dx.doi.org/10.1007/s42399-021-00964-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

AbstractThe so-called long COVID-19 is a set of symptoms that accompanies the patient even for months after discharge from the hospital. These symptoms include easy muscle fatigue, moderate breathlessness, persistent headache, the feeling of a foggy head, and the development of psychiatric disorders. In general, the quality of life of at least half of the patients who come out of the COVID-19 syndrome, both mild and severe, shows a markedly worsening despite having passed a difficult physical and psychological test. Among all the neurological disorders that can most frequently be found in the long COVID-19, it is important to consider the persistent headache symptomatology as a possible chronic sequela of the infection. Since there is not a definition in the International Headache Society classification of this type of headache, we must focus our attention on this long-COVID-19 headache especially because clinical studies are being planned to collect big data for the International Headache Society Classification Committee.

11

Simoneaux, Richard, and Steven L. Shafer. "Long COVID Revisited." ASA Monitor 86, no. 6 (June 1, 2022): 1–5. http://dx.doi.org/10.1097/01.asm.0000833688.97991.37.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Taribagil, Priyal, Dean Creer, and Hasan Tahir. "‘Long COVID’ syndrome." BMJ Case Reports 14, no. 4 (April 2021): e241485. http://dx.doi.org/10.1136/bcr-2020-241485.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

SARS-CoV-2 has resulted in a global pandemic and an unprecedented public health crisis. Recent literature suggests the emergence of a novel syndrome known as ‘long COVID’, a term used to describe a diverse set of symptoms that persist after a minimum of 4 weeks from the onset of a diagnosed COVID-19 infection. Common symptoms include persistent breathlessness, fatigue and cough. Other symptoms reported include chest pain, palpitations, neurological and cognitive deficits, rashes, and gastrointestinal dysfunction. We present a complex case of a previously well 28-year-old woman who was diagnosed with COVID-19. After resolution of her acute symptoms, she continued to experience retrosternal discomfort, shortness of breath, poor memory and severe myalgia. Investigations yielded no significant findings. Given no alternative diagnosis, she was diagnosed with ‘long COVID’.

13

Tammaro, Antonella, Francesca Romana Parisella, and Ganiyat Adenike Ralitsa Adebanjo. "Cutaneous long COVID." Journal of Cosmetic Dermatology 20, no. 8 (June 26, 2021): 2378–79. http://dx.doi.org/10.1111/jocd.14291.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Murray, Terry. "Unpacking “long COVID”." Canadian Medical Association Journal 193, no. 9 (February 28, 2021): E318—E319. http://dx.doi.org/10.1503/cmaj.1095923.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Naeije, Robert, and Sergio Caravita. "Phenotyping long COVID." European Respiratory Journal 58, no. 2 (July 8, 2021): 2101763. http://dx.doi.org/10.1183/13993003.01763-2021.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Gerloff, Christian. "Long-COVID-19." InFo Neurologie + Psychiatrie 24, no. 1 (January 2022): 3. http://dx.doi.org/10.1007/s15005-021-2215-y.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Nath, Avindra. "Long-Haul COVID." Neurology 95, no. 13 (August 11, 2020): 559–60. http://dx.doi.org/10.1212/wnl.0000000000010640.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Kovac, Adam. "Long COVID Update." Brain & Life 18, no. 6 (December 2022): 28–32. http://dx.doi.org/10.1097/01.nnn.0000904776.13569.ed.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Spyropoulos M.S, Vasileios, Agathi Spiropoulou M.S, Georgia Spyropoulou, Dimosthenis Lykouras, Kiriakos Karkoulias, and Kostas Spiropoulos. "Long Covid-19." Archives of Pulmonology and Respiratory Medicine 4, no. 1 (2021): 16–20. http://dx.doi.org/10.22259/2639-362x.0401004.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Digeronimo, Sharyn. "Long COVID Responses." Brain & Life 19, no. 1 (February 2023): 4. http://dx.doi.org/10.1097/01.nnn.0000920128.62160.41.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Ehrlich, Melanie. "Long COVID Responses." Brain & Life 19, no. 1 (February 2023): 4. http://dx.doi.org/10.1097/01.nnn.0000920132.41294.08.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Roth, Alan, Pan San Chan, and Wayne Jonas. "Addressing the Long COVID Crisis: Integrative Health and Long COVID." Global Advances in Health and Medicine 10 (January 2021): 216495612110565. http://dx.doi.org/10.1177/21649561211056597.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

While COVID-19 has killed millions of people globally, its lasting effects on the health and well-being of entire populations are just becoming clear. As many as 30% of those diagnosed with COVID-19 report continuing health-related problems, regardless of the severity of the initial infection. Given the infection rate in the world, that translates to between 5.4 and 17.9 million globally; about 700 000 in the US. The syndrome goes by many names; here we call it “long COVID.” Patients experience a wide range of symptoms, including serious organ system effects such as pulmonary fibrosis, myocarditis, new diabetes diagnoses, stroke, and other cerebrovascular events. They also experience ongoing pain, fatigue, and cognitive dysfunction. We suggest here that these patients require an integrative health approach, one that combines traditional medical management, non-pharmacological approaches, and behavior and lifestyle changes. Such an approach has been shown to be beneficial in other chronic illnesses such as fibromyalgia, chronic fatigue syndrome, and post-Lyme disease.

23

Pellino, Stefania, Margherita Luciano, Rosamaria Luciano, Erika Mancini, Maria Concetta Conte, Gennaro Volpe, and Tommaso Zerella. "Long-COVID-19 Symptoms after Infection in COVID Long-Haulers." Open Journal of Epidemiology 11, no. 04 (2021): 473–82. http://dx.doi.org/10.4236/ojepi.2021.114038.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Wagner, Hans-Otto. "Hausärztliche Handlungsempfehlung: Post-Covid/Long-Covid." Zeitschrift für Komplementärmedizin 14, no. 02 (February 2022): 20–23. http://dx.doi.org/10.1055/a-1840-8654.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

SummaryDie Coronavirus-Krankheit 2019 (Covid-19) wird oft als Multiorgan-Krankheit mit einem breiten Spektrum von Manifestationen angesehen. Ähnlich wie bei anderen Infektionskrankheiten kann Covid-19 für einen Teil der Erkrankten längerfristige Auswirkungen auf die Lebensqualität haben. Dieser Beitrag stellt die relevanten hausärztlichen Handlungsempfehlungen aus der S1-Leitlinie vor (AWMF-Register Nr. 020/027 Version 1–07/2021, [1]). Die Therapie orientiert sich an den Symptomen. Für eine spezifische Therapie gibt es bislang noch keine wissenschaftlich belastbaren Belege. Therapieziele sollten eine Symptomlinderung sowie die Vermeidung einer Chronifizierung sein.

25

Gupta, Sashi B., M. Subramanyam, S. Preeti, Suganya PP Krishna Pillai, Garapati N. Sowmya, and M. Chandrashekar. "Post-COVID–Long COVID—What More?" Indian Journal of Private Psychiatry 16, no. 2 (August 31, 2022): 85–86. http://dx.doi.org/10.5005//jp-journals-10067-0114.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Gupta, Sashi B., M. Subramanyam, S. Preeti, Suganya PP Krishna Pillai, Garapati N. Sowmya, and M. Chandrashekar. "Post-COVID–Long COVID—What More?" Indian Journal of Private Psychiatry 16, no. 2 (August 31, 2022): 85–86. http://dx.doi.org/10.5005/jp-journals-10067-0114.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Köllner, Volker. "S1-Leitlinie »Post-COVID / Long-COVID«." Ärztliche Psychotherapie 16, no. 4 (November 2021): 264–66. http://dx.doi.org/10.21706/aep-16-4-264.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Wagner, Hans-Otto. "Hausärztliche Handlungsempfehlung: Post-COVID/Long-COVID." Allgemeinmedizin up2date 02, no. 04 (November 2021): 302–6. http://dx.doi.org/10.1055/a-1550-6717.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Koczulla, A. R., T. Ankermann, U. Behrends, P. Berlit, S. Böing, F. Brinkmann, C. Franke, et al. "S1-Leitlinie „Post-COVID/Long-COVID“." Der Chirurg 93, no. 1 (January 2022): 101–2. http://dx.doi.org/10.1007/s00104-021-01543-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Hugon, Jacques. "COVID 19 : COVID long et neurologie." Revue Neurologique 178 (April 2022): S160—S161. http://dx.doi.org/10.1016/j.neurol.2022.02.056.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Köllner, Volker. "S1-Leitlinie »Post-COVID / Long-COVID«." Ärztliche Psychotherapie 18, no. 1 (February 2023): 65–67. http://dx.doi.org/10.21706/aep-18-1-65.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Schütz, Burkhard, and Meike Crecelius. "Long-COVID und Post-COVID-Syndrom." Zeitschrift für Orthomolekulare Medizin 21, no. 01 (March 2023): 8–12. http://dx.doi.org/10.1055/a-2009-3541.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

ZusammenfassungUnter dem Post-COVID-Syndrom (PCS) versteht man eine länger als 12 Wochen anhaltende Symptomatik mit Fatigue, Kurzatmigkeit, eingeschränkter Leistungsfähigkeit u. a., die bei rund 15% der Patienten nach einer akuten Infektion mit SARS-CoV-2 auftritt. Als Ursache werden Veränderungen im Mikrobiom und Störungen des Tryptophanstoffwechsels diskutiert, welche zu einer vermehrten Umwandlung von Tryptophan in prooxidativ und proinflammatorisch wirkende Abbauprodukte führen. Nach aktuellen Studien können infolge der Infektion latente Viren wie Epstein-Barr-, Cytomegalie- und Varizella-Zoster-Virus reaktiviert werden und PCS-typische Symptome auslösen. Eine überschießende Entzündungsreaktion bei COVID-19 führt zur Bildung von Autoantikörpern, die durch Einschränkung der Immunantwort die Virusbekämpfung erschweren. Therapeutisch kann eine Supplementierung von Mikronährstoffen wie Vitamin C, D, E, B6, B12, ω-3-Fettsäuren und Coenzym Q10 sinnvoll sein.

33

Singh, Carter. "Long COVID: playing the long game." British Journal of General Practice 71, no. 712 (October 28, 2021): 507. http://dx.doi.org/10.3399/bjgp21x717521.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Makoni, Munyaradzi. "A long journey to long COVID." Lancet Respiratory Medicine 11, no. 1 (January 2023): 21–22. http://dx.doi.org/10.1016/s2213-2600(22)00499-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Sivyakova, Olga N., Elena S. Skripkina, and Olga V. Voronova. "A clinical case of multiple predictors long-COVID-19." Clinical review for general practice 3, no. 5 (May 28, 2022): 23–26. http://dx.doi.org/10.47407/kr2022.3.5.00159.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The aim is to demonstrate the case of multiple predictors of long-COVID-19, to try to explain the data of laboratory and instrumental research methods, the failure of antiarrhythmic therapy. Features of the clinical case: an elderly patient was not vaccinated against COVID-19, suffered from hypertension and obesity for a long time, was hospitalized with COVID-19, complicated by community-acquired pneumonia of moderate severity. Subsequently, atrial fibrillation developed, which could not be eliminated. Long-COVID risk factors: female gender, polymorbid background, elevated C-reactive protein levels, neutrophilosis and lymphopenia occurred in the presented clinical case.

36

Sarıoğlu, Nurhan, Gülden Deniz Aksu, Hikmet Çoban, Erdoğan Bülbül, Gülen Demirpolat, Ayşegül Tuğçe Arslan, and Fuat Erel. "Clinical and radiological outcomes of long-COVID: Is the post-COVID fibrosis common?" Tuberk Toraks 71, no. 1 (March 10, 2023): 48–57. http://dx.doi.org/10.5578/tt.20239907.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

O’Keefe, Louise C. "Post-Acute COVID 19 Syndrome, ‘Long COVID’." Workplace Health & Safety 71, no. 5 (April 27, 2023): 263. http://dx.doi.org/10.1177/21650799231164605.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Bopp, Katrin, and Andrea Meienberg. "Medikamentöse Behandlung von Long-COVID/Post-COVID." Revue Médicale Suisse 20, no. 858 (2024): 178–79. http://dx.doi.org/10.53738/revmed.2024.20.858.178.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Malyavin, Malyavin A. G. "Consequences of COVID-19: prevalence and approaches to Long-COVID symptoms therapy." Therapy 10_2022 (January 17, 2022): 148–59. http://dx.doi.org/10.18565/therapy.2021.10.148-159.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

PATIL, SARANG. "LONG COVID: A LONG RACE TO WIN." CHEST 164, no. 4 (October 2023): A5822—A5823. http://dx.doi.org/10.1016/j.chest.2023.07.3754.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Freisleben, Christian F. "Long COVID braucht Rehabilitation." Das österreichische Gesundheitswesen ÖKZ 62, no. 3-4 (March 2021): 39–40. http://dx.doi.org/10.1007/s43830-021-0028-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Goldman, Ran D. "Long COVID in children." Canadian Family Physician 68, no. 4 (April 2022): 263–65. http://dx.doi.org/10.46747/cfp.6804263.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Voogd, Caroline. "Taking long COVID seriously." British Journal of Child Health 3, no. 2 (April 2, 2022): 57. http://dx.doi.org/10.12968/chhe.2022.3.2.57.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Suparti, Luciana Tati, Maria Yunita Indriarini, and Yosi Maria Wijaya. "KARAKTERISTIK PENDERITA LONG COVID." Jurnal Kesehatan 10, no. 1 (April 20, 2022): 60–66. http://dx.doi.org/10.55912/jks.v10i1.53.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The COVID-19 disease is still unclear, including the long-term impact on its survivors. The further impact of survivors of COVID-19 or long covid is currently being studied by scientists worldwide. The phenomenon about the complaints of COVID-19 survivors that occurred during the pandemic varied greatly. The purpose of this study was to determine the characteristics of long covid sufferers which include various symptoms such as shortness of breath, fatigue, cough, headache, joint pain, muscle pain, difficulty thinking, anxiety, fever, stress, and chest palpitations. This research method is quantitative with descriptive design, where data collection using accidental sampling technique is obtained by 85 respondents participating in this study. This study used a questionnaire as a data collection tool and the data were analysed univariately by presenting the variable frequency distribution. The results showed that the number of patients with long covid symptoms who showed the most symptoms was fatigue (83.5%). The researcher suggests that further researchers examine the characteristics of other long covid and the direct impact on COVID-19 survivors with a larger population with different variables

45

Couzin-Frankel, Jennifer. "Clues to long COVID." Science 376, no. 6599 (June 17, 2022): 1261–65. http://dx.doi.org/10.1126/science.add4297.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Grabmann, Sonja. "Aktueller Stand Long Covid." Erfahrungsheilkunde 71, no. 05 (October 2022): 275–82. http://dx.doi.org/10.1055/a-1840-8792.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

ZusammenfassungZu Beginn der Covid-19-Pandemie war es die akute Infektion, die im Fokus des Interesses lag, doch der Blickwinkel hat sich geändert. Nach der Infektion können bei den Betroffenen Beeinträchtigungen sowohl auf körperlicher als auch auf geistiger Ebene bestehen bleiben – das sog. „Long-Covid-Syndrom“ oder „Post-Covid-Syndrom“. Das Gesundheitswesen forscht zu Ursachen und Therapiemöglichkeiten. In der Praxis hat sich gezeigt, dass bisher gut etablierte naturheilkundliche Verfahren einen positiven Beitrag zur Therapie von Patienten mit Long Covid leisten. Gerade die Kombination von Schulmedizin und Naturheilkunde im Sinne eines integrativen Therapieansatzes kann ein breites Spektrum zielgerichteter Behandlungsmaßnahmen bieten, die dem Ausmaß der von Patienten als zum Teil sehr belastend empfundenen Folgen der Covid-19-Infektion mit seiner Bandbreite an Symptomen gerecht werden könnte.

47

Friedrich, Uwe. "Homöopathie bei Long Covid." Erfahrungsheilkunde 71, no. 05 (October 2022): 264–68. http://dx.doi.org/10.1055/a-1835-6276.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

ZusammenfassungLong Covid ist in den ersten Monaten nach Corona-Infektion oder Corona-Impfung sehr gut homöopathisch zu behandeln. Der Beitrag stellt die am häufigsten angezeigten Mittel zur Heilung von Long Covid vor und erläutert das zugrunde liegende homöopathische Behandlungskonzept. Dieses besteht aus Gabe der passenden Nosode, des passenden spezifischen homöopathischen Mittels und fallweise einer Behandlungsbegleitung mit „Kraftmitteln“. Sehr langwierige Long-Covid-Verläufe werden häufig verkompliziert durch Exazerbationen alter chronischer Krankheiten, neuer Traumatisierungen und wiederholter Impfungen. Eine erfolgreiche homöopathische Behandlung ist auch hier möglich, bedarf aber großer Erfahrung.

48

Ainsworth, Claire. "Grappling with long covid." New Scientist 256, no. 3408 (October 2022): 34. http://dx.doi.org/10.1016/s0262-4079(22)01859-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Chambers, Patrick W. "Long Covid, Short Magnesium." OALib 09, no. 05 (2022): 1–25. http://dx.doi.org/10.4236/oalib.1108736.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Tulp, Edith, and Jeroen Wagenaar. "Verpleegkundigen met long covid." Nursing 28, no. 4 (March 30, 2022): 39–44. http://dx.doi.org/10.1007/s41193-022-0046-y.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "Covid long"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями